Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

Active:	No
Cancer Type:	Leukemia	NCT ID:	NCT04778397
Trial Phases:	Phase III	Protocol IDs:	GS-US-546-5857 (primary) NCI-2021-03967 2020-003949-11
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Gilead
NCI Full Details:	http://clinicaltrials.gov/show/NCT04778397

Summary

The goal of this clinical study is to compare the effectiveness of the study drugs,
magrolimab in combination with azacitidine, versus venetoclax in combination with
azacitidine in participants with previously untreated TP53 mutant acute myeloid leukemia
(AML).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.